A Phase II Study of Sunitinib Malate in Patients With Renal Cell Carcinoma and Unresectable Primary Tumors.

Trial Profile

A Phase II Study of Sunitinib Malate in Patients With Renal Cell Carcinoma and Unresectable Primary Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2014

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 15 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 15 Oct 2012 Planned End Date changed from 1 Dec 2012 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top